265 related articles for article (PubMed ID: 23160854)
21. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
[TBL] [Abstract][Full Text] [Related]
22. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
23. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell-based vaccine for pancreatic cancer in Japan.
Okamoto M; Kobayashi M; Yonemitsu Y; Koido S; Homma S
World J Gastrointest Pharmacol Ther; 2016 Feb; 7(1):133-8. PubMed ID: 26855819
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Yasukawa M; Fujiwara H; Ochi T; Suemori K; Narumi H; Azuma T; Kuzushima K
Am J Hematol; 2009 May; 84(5):314-5. PubMed ID: 19338044
[No Abstract] [Full Text] [Related]
29. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
31. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y; Tsuboi A; Murakami M; Hirai M; Tominaga N; Nakajima H; Elisseeva OA; Masuda T; Nakano A; Kawakami M; Oji Y; Ikegame K; Hosen N; Udaka K; Yasukawa M; Ogawa H; Kawase I; Sugiyama H
Int J Hematol; 2003 Jul; 78(1):56-61. PubMed ID: 12894852
[TBL] [Abstract][Full Text] [Related]
32. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
33. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
34. [Cancer antigen WT1-targeting treatment for the malignancies].
Oka Y; Kawase I
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
[TBL] [Abstract][Full Text] [Related]
35. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
[TBL] [Abstract][Full Text] [Related]
36. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
Kato Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
[TBL] [Abstract][Full Text] [Related]
37. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
38. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
39. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
Oji Y; Kagawa N; Arita H; Naka N; Hamada KI; Outani H; Shintani Y; Takeda Y; Morii E; Shimazu K; Suzuki M; Nishida S; Nakata J; Tsuboi A; Iwai M; Hayashi S; Imanishi R; Ikejima S; Kanegae M; Iwamoto M; Ikeda M; Yagi K; Shimokado H; Nakajima H; Hasegawa K; Morimoto S; Fujiki F; Nagahara A; Tanemura A; Ueda Y; Mizushima T; Ohmi M; Ishida T; Fujimoto M; Nonomura N; Kimura T; Inohara H; Okada S; Kishima H; Hosen N; Kumanogoh A; Oka Y; Sugiyama H
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672344
[TBL] [Abstract][Full Text] [Related]
40. Delayed-Type Hypersensitivity: An Excellent Indicator of Anti-tumor Immunity With Wilms' Tumor 1 (WT1) Dendritic Cell Vaccine Therapy.
Nagai H; Karube R
Cureus; 2023 Nov; 15(11):e49221. PubMed ID: 38143707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
